Trial Profile
A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared with empagliflozin QD in Type-2-diabetes-mellitus patients with mild to moderate hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2022
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary) ; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 11 Jul 2022 Results assessing differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and SGLT2 on multiple parameters published in the Diabetes Care
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2019 Status changed from recruiting to active, no longer recruiting.